Overview Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study Status: Unknown status Trial end date: 2020-01-01 Target enrollment: Participant gender: Summary To study the impact of mirabegron, a B3-adrenoceptor agonist, in the treatment of ED in patients with LUTS secondary to BPH and concomitant ED. Phase: Phase 2 Details Lead Sponsor: Mansoura UniversityTreatments: MirabegronTamsulosin